Ahmet Toprak, MD
Cardiovascular Disease · Seattle, WANPI 1871728220
Payments from drug & device makers
Across 32 payments — averaging $107.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Astellas Pharma US Inc$245
- Boston Scientific$141
- AstraZeneca$14
- Medtronic$13
What the payments were for
- Travel & lodging$2,26366%
- Food & beverage$91327%
- Education$2598%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 24 | $3,022 |
| Astellas Pharma US Inc | 3 | $245 |
| Boston Scientific | 3 | $141 |
| AstraZeneca | 1 | $14 |
| Medtronic | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Cardiovascular- Research only$1,125
- Allure CRT Pacemaker$1,122
- Assurity Pacemaker$153
- Watchman$106
- MitraClip$102
How this compares
$3,435 in reported general payments places this provider in the 70th percentile of 370 cardiovascular disease providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 183 | $260,371 |
| EliquisApixaban | 165 | $244,111 |
| Repatha SureclickEvolocumab | 25 | $29,272 |
| JardianceEmpagliflozin | 15 | $25,631 |
| Praluent PenAlirocumab | 15 | $10,512 |
| Metoprolol Succinate | 750 | $8,410 |
| Atorvastatin Calcium | 502 | $4,551 |
| Potassium Chloride | 216 | $3,762 |
| Losartan Potassium | 319 | $2,634 |
| Torsemide | 75 | $2,595 |
| Amlodipine Besylate | 334 | $2,359 |
| Ezetimibe | 116 | $2,239 |
| Lisinopril | 258 | $1,826 |
| Furosemide | 305 | $1,699 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 74 | $1,652 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Seattle
- Francis KimSeattle$1.7M
- Kelley BranchSeattle$715K
- Mariko HarperSeattle$453K
- David OwensSeattle$325K
- John PetersenSeattle$309K
- Sara WeissSeattle$266K
- Gary OppenheimSeattle$153K
- Bhanu GuptaSeattle$147K
- David LamSeattle$120K
- Erik WissnerSeattle$117K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.